Introduction to the Class Action for Sage Therapeutics, Inc.
Attention all investors holding shares of Sage Therapeutics, Inc. (NASDAQ: SAGE)! There is a pivotal class action that has been initiated regarding potential losses you may have sustained. The Gross Law Firm has put out a notice to shareholders, encouraging anyone affected to reach out about possible lead plaintiff appointments. This opportunity provides a proper channel for individuals who may want to partake in the recovery process.
Understanding the Class Period
The class period for this action spans from April 12, 2021 to July 23, 2024. If you purchased shares during this window, it is crucial to register and make your concerns known. Taking timely action can have a significant impact on your eligibility for recovery.
Owner Eligibility
Shareholders should not hesitate to contact The Gross Law Firm about their investment losses. Participation in this class action does not require you to be a lead plaintiff; your claim can still proceed regardless of the role you take within the class.
Allegations Against Sage Therapeutics
The allegations detailed in the complaint paint a concerning picture for investors. They indicate that the company made materially false or misleading assertions regarding their products, particularly Zuranolone and SAGE-718. These assertions misled investors into believing that the company's treatments were more effective and regulatory approvals were more likely than what was true.
Specific Concerns Raised
Specifically, the complaint outlines claims that Zuranolone, developed for postpartum depression, was not as effective for Major Depressive Disorder (MDD) as stated. This discrepancy raised serious doubts about the likelihood of FDA approval based on the company's previous statements.
Similarly, SAGE-718, designed for Mild Cognitive Impairment, was alleged to be less effective than claimed. The misleading information regarding SAGE-324’s efficacy in treating essential tremors also raised concern among investors. Each of these products was touted as having strong efficacy, placing the company's public statements under scrutiny.
Important Deadlines to Note
The deadline for shareholders to register for participation in this class action is approaching quickly on October 28, 2024. It is imperative that affected shareholders act without delay to ensure their voices are heard.
Next Steps for Shareholders
Once registered, shareholders will benefit from a portfolio monitoring system designed to provide updates about the case's progress. Participation is free, and there is no obligation to assume a lead role. The firm will guide you through necessary steps, empowering you to advocate for your rights.
Why Choose The Gross Law Firm?
You may be wondering why The Gross Law Firm is the right choice for navigating this class action. Their national recognition stems from a relentless commitment to safeguarding investors' rights against fraudulent practices. The firm prioritizes transparency, aiming to uphold corporate accountability through legal means.
Contact Information for Further Assistance
If you have questions or need more information, you can reach out to The Gross Law Firm. Their office is conveniently located:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (646) 453-8903
Frequently Asked Questions
What is the purpose of this class action?
This class action aims to recover losses for shareholders who were misled by Sage Therapeutics regarding the efficacy of its products.
Who can join the class action?
Any shareholders who purchased SAGE shares during the specified class period can participate.
Is there a cost to participate?
No, there is no cost or obligation to join the class action.
What should I do if I want to participate?
Contact The Gross Law Firm and register your information as a shareholder.
What is the deadline for registration?
The registration deadline for the class action is October 28, 2024.
